Dr. Mikko Hölttä joined AstraZeneca Gothenburg in March 2015 as senior scientist in the nucleotide bioanalysis group, working with pre-clinical PK/TK bioanalysis for new modality projects including oligonucleotides, modified RNA, CRISPR-CAS9, anti-miR, and proteins/peptides. Since March 2017, he has been working in the translational biomarkers & bioanalysis team in AZ Gothenburg providing analytical support for new
modality projects and with development and validation of biomarkers for safety studies.
He received his Ph.D. in medicine in 2014, working with clinical biomarkers discovery for Alzheimer’s disease and other neurogenerative diseases from Sahlgrenska Academy, University of Gothenburg, and then continued to work as a research scientist in neuroscience & physiology. He has a master’s degree in pharmaceutical biosciences from Sahlgrenska Academy in 2008.